phase1-2 · 2024
MSC and cell secretome in atopic dermatitis
Small studies report reduced severity scores in some patients; better-controlled studies are needed for confirmation.
PubMedTreatment example
Care journey example: atopic dermatitis
What a person with atopic dermatitis actually goes through, from reviewing standard care to considering cell research.
In short
Standard care — emollients, topical anti-inflammatories and biologics — should be optimised first. EHL BIO's published work in this area is animal and immune-mechanism research, not confirmed human evidence.
Step by step
Timings are a general example and may change with documents and clinical judgement.
- 01
Send your question and basic information
Day 1Complete the information-consultation form with your symptoms, how long you have had them, current medicines and previous treatments. The EHL Thailand information team replies in your dashboard. This step is educational information, not a diagnosis.
Who is involved: You + EHL Thailand information team
- 02
Collect your medical documents
Week 1–2Prepare discharge/treatment summaries, blood results, X-ray or MRI images and your medicine list. The more complete the records, the more accurate the eligibility review. Documents are used only with your consent (PDPA).
Who is involved: You + your current treating doctor
- 03
Review the research evidence together
Week 2The team explains that EHL BIO's published work — adipose-derived stem cells regulating B-lymphocyte maturation and Th1/Th2 balance — is preclinical, and separates it clearly from patient trials.
Who is involved: Information team + content review panel
- 04
Clinical eligibility screening
Week 3–4A dermatologist assesses severity (e.g. EASI/SCORAD), secondary infection and response to standard care, including whether biologics with stronger evidence are appropriate.
Who is involved: The doctor or clinic responsible for care in Korea
- 05
Informed consent before deciding
Before travellingBefore deciding you should receive documents stating that the treatment is investigational and not registered in Thailand, the risks, the alternatives, the full costs, and what is still unknown. No outcome guarantee should ever be given.
Who is involved: You + the treating doctor
- 06
Treatment and follow-up
From treatment day to 12 monthsRash severity, itch, sleep and topical use are followed at 1, 3 and 6 months, with flare-ups recorded.
Who is involved: Treating doctor + your doctor in Thailand
Documents to prepare
- Photos of the rash during flare and remission
- List of topical and oral medicines already tried, with results
- Allergy or IgE test results if available
- A trigger log: food, weather, stress
Questions to ask your doctor
- Which standard treatments have not been tried yet?
- What level of human evidence exists for cell therapy in this disease?
- What are the infection and immune-reaction risks?
- If there is no response, what is the next plan?
Limits you must know
- Stem cell treatment for these conditions remains investigational; it is not standard care.
- EHL Thailand is an information and consultation channel, not a clinic, and does not diagnose or prescribe.
- EHL BIO pipeline cell products have no published Thai registration status.
- The timings shown are a general example and may change with documents, extra tests and clinical judgement.
Related disease page
Atopic Dermatitis
A chronic inflammatory skin disease characterised by itch and dry skin.
Research cited in this journey
review · 2026
EHL BIO patents and research papers
EHL BIO publishes a list of patents and research papers in the R&D section of its corporate website. Readers should verify the current list at the source before citing.
EHL BIO — Patents and Research Papersphase2 · 2024
ADSTEM Inj.: clinical trials in atopic dermatitis (hospital information)
The hospital's affiliated research centre states Phase 1 completed in 2017, Phase 2 completed in 2023 and a Phase 3 IND submitted in 2024. No accessible peer-reviewed results confirm efficacy, and this is not approved treatment in Thailand.
EHL BIO (research page)Experts involved
Profiles show only details checkable against public sources.
EHL BIO Stem Cell Research Institute
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentEHL Thailand Medical Information Team
Writes and reviews disease pages and stem cell topics
Evidence levels, regulatory status, and separating hospital information from medical information
Experts behind this content
EHL Thailand Medical Information Team — Evidence levels, regulatory status, and separating hospital information from medical information
EHL BIO scientific information is compiled alongside public information from its research team and GMP centre. See the full expert panel
Frequently asked questions
Last updated 3 Sept 2026